The ABHD12 Knockout HT29 Polyclonal Cells constitute a CRISPR/Cas9-mediated loss-of-function model designed to disrupt the ABHD12 gene within a heterogeneous polyclonal cell population. This product provides a pool of edited cells, each harboring a distinct gene disruption event, enabling robust functional studies without clonal isolation bottlenecks. The knockout population eliminates wild-type ABHD12 expression, allowing researchers to interrogate the gene??s role in endocannabinoid signaling and lipid metabolism directly in a human colorectal adenocarcinoma context. As a polyclonal knockout, the model avoids artifacts associated with single-cell clonal selection and better reflects the genetic diversity encountered in tumor biology, making it an ideal tool for pathway analysis and drug screening.
The host cell line, HT29, is an established human colorectal adenocarcinoma line originally derived from a primary colon tumor of a 44-year-old female patient. HT29 cells serve as a well-characterized model of intestinal epithelial physiology, retaining the capacity for enterocytic differentiation under appropriate culture conditions. Their epithelial origin makes them particularly suitable for studying colorectal cancer biology, including processes such as proliferation, migration, invasion, and metabolic reprogramming. The integration of ABHD12 knockout within this background creates a powerful system to dissect how endocannabinoid modulation influences tumor cell behavior and therapeutic responses.
ABHD12 encodes a serine hydrolase that preferentially hydrolyzes the monoacylglycerol 2-arachidonoylglycerol (2-AG), a major endocannabinoid lipid mediator, into arachidonic acid and glycerol. By regulating 2-AG tone, ABHD12 directly controls the activation of cannabinoid receptors CB1 and CB2, which are coupled to downstream signaling cascades including the MAPK/ERK pathway, cAMP/PKA axis, and prostaglandin synthesis. ABHD12 activity is itself modulated by upstream inflammatory signals such as TNF-??, IL-1??, and lipopolysaccharide (LPS), as well as by PPAR agonists. It functionally interacts with monoacylglycerol lipase (MGLL), another key hydrolase in the 2-AG degradation pathway. Consequently, ABHD12 sits at the nexus of endocannabinoid, lipid, and inflammatory signaling networks, with implications for neuroinflammation and cancer progression.
In the HT29 colorectal adenocarcinoma model, ABHD12 knockout enables the dissection of oncogenic mechanisms driven by aberrant endocannabinoid signaling. Loss of ABHD12 is predicted to elevate 2-AG levels, leading to sustained CB1/CB2 receptor activation and altered downstream proliferation and survival programs. This perturbation can augment or attenuate tumorigenic phenotypes, providing insights into the dual roles of cannabinoid signaling in cancer. Moreover, because HT29 cells are capable of differentiation, this knockout system permits the study of ABHD12 in both undifferentiated, proliferative tumor cells and in more differentiated, enterocyte-like states, thereby capturing context-dependent functions of lipid signaling in tumor heterogeneity and immune evasion.
This knockout cell product supports a broad array of hypothesis-driven research applications, including quantification of 2-AG by LC-MS to confirm metabolic shifts, immunoblotting for phosphorylated ERK and AKT to map signal transduction changes, and functional assays such as MTT/BrdU proliferation, Boyden chamber migration/invasion, and annexin V/PI apoptosis profiling. It is also well-suited for ABHD12 inhibitor screening, drug sensitivity testing, and genome-wide transcriptomic profiling via RNA-seq to identify novel downstream effectors. For further details on experimental validation or to discuss custom applications, please contact Ascent Research.
